SpineGuard announced the filing of its 510K regulatory dossier with the FDA, seeking the authorization to commercialize its Threaded PediGuard device for anterior approach instrumented spine surgery.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2335 EUR | 0.00% | 0.00% | +16.98% |
04-17 | SpineGuard SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | SpineGuard SA announced that it expects to receive ?1.998 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+16.98% | 11.91M | |
+73.50% | 12.41B | |
-19.26% | 7.87B | |
+2.40% | 6.37B | |
+3.66% | 5.81B | |
+11.89% | 5.36B | |
+37.45% | 4.92B | |
-19.73% | 4.02B | |
-35.58% | 2.43B | |
+0.74% | 2.02B |
- Stock Market
- Equities
- ALSGD Stock
- News SpineGuard
- SpineGuard Files its “510K” Dossier for the Clearance of its “Threaded PediGuard” in Anterior Approach Spine Surgery